Indication
Chronic hepatitis C - genotype 6
Chronic hepatitis C – genotype 6 is a persistent liver infection characterized by detectable hepatitis C viral RNA for at least six months, specifically caused by genotype 6 of the single-stranded RNA hepatitis C virus. Read more about Chronic hepatitis C - genotype 6
6 drugs 3 manufacturers
Drugs that treat it
Common Chronic hepatitis C - genotype 6 therapies.
EPCLUSA (sofosbuvir/velpatasvir)
VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)
MAVYRET (glecaprevir/pibrentasvir)
LEDIPASVIR-SOFOSBUVIR (ledipasvir/sofosbuvir)
SOFOSBUVIR-VELPATASVIR (sofosbuvir/velpatasvir)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic hepatitis C – genotype 6 is a persistent liver infection characterized by detectable hepatitis C viral RNA for at least six months, specifically caused by genotype 6 of the single-stranded RNA hepatitis C virus.
Primarily endemic to Southeast Asia and southern China, this subtype targets the hepatic system and frequently demonstrates marked genetic diversity across its recognized subtypes.
Pathophysiologically, persistent intrahepatic viral replication and host immune-mediated inflammation drive progressive hepatocellular injury, which can advance silently over decades to hepatic fibrosis, cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
- nih.gov
Chronic hepatitis C – genotype 6 is a persistent liver infection characterized by detectable hepatitis C viral RNA for at least six months, specifically caused by genotype 6 of the single-stranded RNA hepatitis C virus
- hiv.gov
Chronic hepatitis C – genotype 6 is a persistent liver infection characterized by detectable hepatitis C viral RNA for at least six months, specifically caused by genotype 6 of the single-stranded RNA hepatitis C virus
- nih.gov
Primarily endemic to Southeast Asia and southern China, this subtype targets the hepatic system and frequently demonstrates marked genetic diversity across its recognized subtypes
- nih.gov
Primarily endemic to Southeast Asia and southern China, this subtype targets the hepatic system and frequently demonstrates marked genetic diversity across its recognized subtypes Pathophysiologically, persistent intrahepatic viral replication and host immune-mediated inflammation drive progressive hepatocellular injury, which can advance silently over decades to hepatic fibrosis, cirrhosis, end-stage liver disease, and hepatocellular carcinoma
- cdc.gov
Pathophysiologically, persistent intrahepatic viral replication and host immune-mediated inflammation drive progressive hepatocellular injury, which can advance silently over decades to hepatic fibrosis, cirrhosis, end-stage liver disease, and hepatocellular carcinoma
Personalize your experience
Follow Chronic hepatitis C - genotype 6 and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.